TL

Tri Locum Partners

North America, New York, United States, New York

Description

Tri Locum is a healthcare investment firm with SEC registration committed to making investments in both public and private opportunities.

Investor Profile

Tri Locum Partners has backed more than 2 startups, with 1 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 1 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Post Ipo Equity, Series C rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biotechnology, Health Care, Pharmaceutical.

Stage Focus

  • Post Ipo Equity (50%)
  • Series C (50%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Genetics
  • Health Diagnostics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Tri Locum Partners frequently co-invest with?

Blue Owl
North America, New York, United States, New York
Co-Investments: 1
LabCorp
North America, North Carolina, United States, Burlington
Co-Investments: 1
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 1
GM
North America, New York, United States, New York
Co-Investments: 1
Bio-Rad Laboratories
North America, California, United States, Hercules
Co-Investments: 1
Atlas Venture
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
LC
North America, Missouri, United States, St Louis
Co-Investments: 1
Deep Track Capital
North America, Connecticut, United States, Greenwich
Co-Investments: 1
Rock Springs Capital
North America, Maryland, United States, Baltimore
Co-Investments: 1

What are some of recent deals done by Tri Locum Partners?

Geneoscopy

Saint Louis, Missouri, United States

Geneoscopy develops a screening methodology to noninvasively diagnose colorectal cancer using biomarkers in stool samples.

BiotechnologyGeneticsHealth CareHealth Diagnostics
Series CJan 8, 2025
Amount Raised: $105,000,000
Korro Bio

Cambridge, Massachusetts, United States

Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.

BiotechnologyHealth CarePharmaceutical
Post Ipo EquityApr 18, 2024
Amount Raised: $70,000,000

Find More Investors Like Tri Locum Partners

Discover similar investors in our database and build your perfect investor list.

Need help with your fundraising strategy?Read our fundraising guides

Tri Locum Partners | Pipeseed